Skip to main content

Table 3 Potential biomarkers for precision treatment with Akt inhibitors

From: Targeting Akt in cancer for precision therapy

Biomarker Cancer types References
PTEN mutation or deficiency Prostate cancer, breast cancer, endometrial cancer, glioblastoma, thyroid cancer, etc. [235]
PIK3CA mutation Breast cancer, ovarian cancer, colorectal cancer, lung cancer, endometrial carcinoma, cervical adenocarcinoma, glioma, head and neck cancer, etc. [234]
Akt1 E17K Breast cancer, ovarian cancer, endometrial carcinoma, meningioma, etc. [232, 240]
Activating Akt1/2 indels Breast cancer, prostate cancer, clear cell renal cancer, etc. [239]
ARID1A/B mutations or deficiency Gastric, ovarian and endometrioid carcinoma, medulloblastoma [245,246,247]
SF3B1 mutation Myelodysplastic/myeloproliferative neoplasms, melanoma, breast cancer, pancreatic cancer, prostate cancer, AML, etc. [254, 255]
NPM1 mutation AML [257]
NM23-H1 Breast cancer, melanoma, etc. [248]
CBL mutation Myeloid neoplasmas [249]
BTK mutation or deficiency Follicular lymphoma [253]
GPS2 mutation Breast cancer, medulloblastoma [250,251,252]
CDH1 mutation or deficiency Gastric cancer, breast cancer, prostate cancer, colorectal cancer, ovarian cancer, etc. [261, 262]
SMAD4 mutation Colorectal cancer, pancreatic cancer [269, 270]
GAB2 mutation or amplification Hematological malignancies, ovarian cancer, lung cancer, neuroblastoma, melanoma, breast cancer [264,265,266,267,268]